These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34063098)

  • 41. Tumor-Associated Macrophage-Mediated Targeted Therapy of Triple-Negative Breast Cancer.
    Niu M; Valdes S; Naguib YW; Hursting SD; Cui Z
    Mol Pharm; 2016 Jun; 13(6):1833-42. PubMed ID: 27074028
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Peptide mediated active targeting and intelligent particle size reduction-mediated enhanced penetrating of fabricated nanoparticles for triple-negative breast cancer treatment.
    Hu G; Chun X; Wang Y; He Q; Gao H
    Oncotarget; 2015 Dec; 6(38):41258-74. PubMed ID: 26517810
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tumor microenvironment-targeted poly-L-glutamic acid-based combination conjugate for enhanced triple negative breast cancer treatment.
    Arroyo-Crespo JJ; Armiñán A; Charbonnier D; Balzano-Nogueira L; Huertas-López F; Martí C; Tarazona S; Forteza J; Conesa A; Vicent MJ
    Biomaterials; 2018 Dec; 186():8-21. PubMed ID: 30278346
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Milk derived colloid as a novel drug delivery carrier for breast cancer.
    Hayashi M; Silanikove N; Chang X; Ravi R; Pham V; Baia G; Paz K; Brait M; Koch WM; Sidransky D
    Cancer Biol Ther; 2015; 16(8):1184-93. PubMed ID: 26046946
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer.
    Dai W; Yang F; Ma L; Fan Y; He B; He Q; Wang X; Zhang H; Zhang Q
    Biomaterials; 2014 Jul; 35(20):5347-5358. PubMed ID: 24726747
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A smart tumor targeting peptide-drug conjugate, pHLIP-SS-DOX: synthesis and cellular uptake on MCF-7 and MCF-7/Adr cells.
    Song Q; Chuan X; Chen B; He B; Zhang H; Dai W; Wang X; Zhang Q
    Drug Deliv; 2016 Jun; 23(5):1734-46. PubMed ID: 25853477
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cholecalciferol-PEG Conjugate Based Nanomicelles of Doxorubicin for Treatment of Triple-Negative Breast Cancer.
    Kutlehria S; Behl G; Patel K; Doddapaneni R; Vhora I; Chowdhury N; Bagde A; Singh M
    AAPS PharmSciTech; 2018 Feb; 19(2):792-802. PubMed ID: 29019073
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Conjugate of Doxorubicin to Albumin-Binding Peptide Outperforms Aldoxorubicin.
    Yousefpour P; Ahn L; Tewksbury J; Saha S; Costa SA; Bellucci JJ; Li X; Chilkoti A
    Small; 2019 Mar; 15(12):e1804452. PubMed ID: 30756483
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis.
    Das S; Tripathi N; Siddharth S; Nayak A; Nayak D; Sethy C; Bharatam PV; Kundu CN
    Apoptosis; 2017 Oct; 22(10):1205-1224. PubMed ID: 28702823
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [(WR)
    Zoghebi K; Aliabadi HM; Tiwari RK; Parang K
    Cells; 2022 Jan; 11(2):. PubMed ID: 35053417
    [TBL] [Abstract][Full Text] [Related]  

  • 51. M
    Liu X; Li P; Huang Y; Li H; Liu X; Du Y; Lin X; Chen D; Liu H; Zhou Y
    Redox Biol; 2024 Feb; 69():102993. PubMed ID: 38104484
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel peptide-doxorubucin conjugates for targeting breast cancer cells including the multidrug resistant cells.
    Soudy R; Chen C; Kaur K
    J Med Chem; 2013 Oct; 56(19):7564-73. PubMed ID: 24028446
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MMPs-specific PEGylated peptide-DOX conjugate micelles that can contain free doxorubicin.
    Lee GY; Park K; Kim SY; Byun Y
    Eur J Pharm Biopharm; 2007 Nov; 67(3):646-54. PubMed ID: 17499491
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Piperlongumine Induces Apoptosis and Synergizes with Doxorubicin by Inhibiting the JAK2-STAT3 Pathway in Triple-Negative Breast Cancer.
    Chen D; Ma Y; Li P; Liu M; Fang Y; Zhang J; Zhang B; Hui Y; Yin Y
    Molecules; 2019 Jun; 24(12):. PubMed ID: 31242627
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
    Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
    J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
    Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
    Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Overcoming multidrug resistance via simultaneous delivery of cytostatic drug and P-glycoprotein inhibitor to cancer cells by HPMA copolymer conjugate.
    Sivak L; Subr V; Tomala J; Rihova B; Strohalm J; Etrych T; Kovar M
    Biomaterials; 2017 Jan; 115():65-80. PubMed ID: 27886555
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Coaxial electrostatic spray-based preparation of localization missile liposomes on a microfluidic chip for targeted treatment of triple-negative breast cancer.
    Wang Q; Xu W; Li Q; He C; Liu Y; Liu J; Wang R; Wu J; Xiang D; Chen C
    Int J Pharm; 2023 Aug; 643():123220. PubMed ID: 37437856
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synergistic anticancer immunity in metastatic triple-negative breast cancer through an in situ amplifying Peptide-Drug Conjugate.
    Kim HR; Park SJ; Cho YS; Ko YG; Kim SY; Byun Y
    J Control Release; 2024 Sep; 375():681-697. PubMed ID: 39094631
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multitargeted Nanoparticles Deliver Synergistic Drugs across the Blood-Brain Barrier to Brain Metastases of Triple Negative Breast Cancer Cells and Tumor-Associated Macrophages.
    Zhang T; Lip H; He C; Cai P; Wang Z; Henderson JT; Rauth AM; Wu XY
    Adv Healthc Mater; 2019 Sep; 8(18):e1900543. PubMed ID: 31348614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.